SG11201407655TA - Therapeutic uses of fibroblast growth factor 21 proteins - Google Patents
Therapeutic uses of fibroblast growth factor 21 proteinsInfo
- Publication number
- SG11201407655TA SG11201407655TA SG11201407655TA SG11201407655TA SG11201407655TA SG 11201407655T A SG11201407655T A SG 11201407655TA SG 11201407655T A SG11201407655T A SG 11201407655TA SG 11201407655T A SG11201407655T A SG 11201407655TA SG 11201407655T A SG11201407655T A SG 11201407655TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- indianapolis
- company
- rule
- eli lilly
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 November 2013 (21.11.2013) WIPOIPCT (10) International Publication Number WO 2013/173158 A1 (51) International Patent Classification: A61K38/18 (2006.01) A61P19/10 (2006.01) A61P19/08 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/040275 9 May 2013 (09.05.2013) English (30) Priority Data: 61/646,974 61/786,939 15 May 2012 (15.05.2012) 15 March 2013 (15.03.2013) English US US (71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US). DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). (72) Inventors: MA, Yanfei Linda; c/o Eli Lilly and Company, Declarations under Rule 4.17: P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). IRIZARRY ROVIRA, Armando Rafael; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). REYNOLDS, Vincent Louis; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) (74) Agents: CASTETTER, Andrea Michelle et al.; Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206- 6288 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) 00 T-H m i> i-H o CJ 0 (54) Title: THERAPEUTIC USES OF FIBROBLAST GROWTH FACTOR 21 PROTEINS ^ (57) Abstract: The present invention relates to therapeutic uses of human fibroblast growth factor 21 (FGF21) proteins.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261646974P | 2012-05-15 | 2012-05-15 | |
| US201361786939P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/040275 WO2013173158A1 (en) | 2012-05-15 | 2013-05-09 | Therapeutic uses of fibroblast growth factor 21 proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407655TA true SG11201407655TA (en) | 2014-12-30 |
Family
ID=48483225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407655TA SG11201407655TA (en) | 2012-05-15 | 2013-05-09 | Therapeutic uses of fibroblast growth factor 21 proteins |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20150141335A1 (en) |
| EP (1) | EP2852398A1 (en) |
| JP (1) | JP2015522539A (en) |
| KR (1) | KR20150002801A (en) |
| CN (1) | CN104302311A (en) |
| AU (1) | AU2013263188A1 (en) |
| BR (1) | BR112014028413A2 (en) |
| CA (1) | CA2869320A1 (en) |
| CL (1) | CL2014002846A1 (en) |
| CO (1) | CO7131381A2 (en) |
| EA (1) | EA201491856A1 (en) |
| HK (1) | HK1202800A1 (en) |
| IL (1) | IL235482A0 (en) |
| MA (1) | MA37506B1 (en) |
| MX (1) | MX2014013913A (en) |
| PE (1) | PE20142432A1 (en) |
| PH (1) | PH12014502537A1 (en) |
| SG (1) | SG11201407655TA (en) |
| TN (1) | TN2014000409A1 (en) |
| WO (1) | WO2013173158A1 (en) |
| ZA (1) | ZA201407532B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8951966B2 (en) | 2011-07-01 | 2015-02-10 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| EP3798228A1 (en) | 2012-11-28 | 2021-03-31 | NGM Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| CN108888757A (en) | 2012-12-27 | 2018-11-27 | 恩格姆生物制药公司 | Method for adjusting bile acid homeostasis and treating bile acid disorder and disease |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| KR102178945B1 (en) | 2013-10-28 | 2020-11-13 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | Cancer models and associated methods |
| BR112016017248A8 (en) | 2014-01-24 | 2018-04-17 | Ngm Biopharmaceuticals Inc | antibody or fragment thereof, binding agent, transgenic animal, hybridoma, vector, pharmaceutical composition, fgf19 and / or fgf21-like signaling induction method, method for activating a klotho beta / fgf receptor complex, method for improving metabolism of glucose in an individual, method of detecting klotho beta, use of antibody or fragment thereof, use of pharmaceutical composition, treatment method and method for improving metabolic parameters |
| US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
| CA2951153A1 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| JP6308699B2 (en) * | 2014-09-08 | 2018-04-11 | 国立大学法人大阪大学 | Preventive or therapeutic agent for demyelinating disease |
| KR102569907B1 (en) | 2014-10-23 | 2023-08-24 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | Pharmaceutical Compositions Comprising Peptide Variants and Methods of Use Thereof |
| WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| EP3377090B1 (en) | 2015-11-09 | 2021-04-07 | NGM Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| EP3503882A4 (en) | 2016-08-26 | 2020-07-29 | NGM Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| CN108324928B (en) * | 2018-03-05 | 2020-09-08 | 哈尔滨医科大学 | Application of recombinant human fibroblast growth factor-5 in promoting fracture healing |
| CN115322794A (en) | 2020-01-11 | 2022-11-11 | 北京质肽生物医药科技有限公司 | Conjugates of fusion proteins of GLP-1 and FGF21 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE554785T1 (en) * | 2007-03-30 | 2012-05-15 | Ambrx Inc | MODIFIED FGF-21 POLYPEPTIDES AND THEIR USE |
| AR087973A1 (en) * | 2011-10-04 | 2014-04-30 | Lilly Co Eli | VARIATIONS OF FACTOR 21 GROWTH OF FIBROBLASTS |
-
2013
- 2013-05-09 PE PE2014001980A patent/PE20142432A1/en not_active Application Discontinuation
- 2013-05-09 MX MX2014013913A patent/MX2014013913A/en unknown
- 2013-05-09 KR KR1020147031701A patent/KR20150002801A/en not_active Application Discontinuation
- 2013-05-09 CA CA2869320A patent/CA2869320A1/en not_active Abandoned
- 2013-05-09 BR BR112014028413A patent/BR112014028413A2/en not_active IP Right Cessation
- 2013-05-09 SG SG11201407655TA patent/SG11201407655TA/en unknown
- 2013-05-09 AU AU2013263188A patent/AU2013263188A1/en not_active Abandoned
- 2013-05-09 US US14/399,037 patent/US20150141335A1/en not_active Abandoned
- 2013-05-09 MA MA37506A patent/MA37506B1/en unknown
- 2013-05-09 JP JP2015512695A patent/JP2015522539A/en not_active Withdrawn
- 2013-05-09 CN CN201380025338.6A patent/CN104302311A/en active Pending
- 2013-05-09 EP EP13724685.6A patent/EP2852398A1/en not_active Withdrawn
- 2013-05-09 EA EA201491856A patent/EA201491856A1/en unknown
- 2013-05-09 WO PCT/US2013/040275 patent/WO2013173158A1/en active Application Filing
-
2014
- 2014-09-30 TN TNP2014000409A patent/TN2014000409A1/en unknown
- 2014-10-16 ZA ZA2014/07532A patent/ZA201407532B/en unknown
- 2014-10-22 CL CL2014002846A patent/CL2014002846A1/en unknown
- 2014-11-03 IL IL235482A patent/IL235482A0/en unknown
- 2014-11-14 PH PH12014502537A patent/PH12014502537A1/en unknown
- 2014-11-14 CO CO14252512A patent/CO7131381A2/en unknown
-
2015
- 2015-04-02 HK HK15103356.5A patent/HK1202800A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TN2014000409A1 (en) | 2015-12-21 |
| HK1202800A1 (en) | 2015-10-09 |
| JP2015522539A (en) | 2015-08-06 |
| PH12014502537A1 (en) | 2015-01-21 |
| AU2013263188A1 (en) | 2014-10-16 |
| CN104302311A (en) | 2015-01-21 |
| BR112014028413A2 (en) | 2017-11-07 |
| MX2014013913A (en) | 2015-02-17 |
| KR20150002801A (en) | 2015-01-07 |
| MA37506B1 (en) | 2017-03-31 |
| EA201491856A1 (en) | 2015-03-31 |
| IL235482A0 (en) | 2014-12-31 |
| CL2014002846A1 (en) | 2015-01-30 |
| ZA201407532B (en) | 2016-05-25 |
| PE20142432A1 (en) | 2015-01-22 |
| MA37506A1 (en) | 2016-01-29 |
| CA2869320A1 (en) | 2013-11-21 |
| WO2013173158A1 (en) | 2013-11-21 |
| EP2852398A1 (en) | 2015-04-01 |
| CO7131381A2 (en) | 2014-12-01 |
| US20150141335A1 (en) | 2015-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201408646VA (en) | Dimeric protein with triple mutations | |
| SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201408124PA (en) | Differentiation of human embryonic stem cells into pancreatic endocrine cells | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201408261UA (en) | Syringe | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201407579QA (en) | Interleukin-2 fusion proteins and uses thereof | |
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport | |
| SG11201408174UA (en) | Antibody formulation | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds |